<DOC>
	<DOCNO>NCT00444509</DOCNO>
	<brief_summary>This single centre , randomise , double blind , two-way crossover study , investigate safety , tolerability , pharmacokinetics pharmacodynamics inhale dry powder GW685698X ( 800 ? g ) contain magnesium stearate . Magnesium stearate excipient add improve physical stability inhale dry powder formulation . Male female patient mild/moderate asthma randomise determine order receive single inhaled administration GW685698X ( 800 ? g ) without magnesium stearate . There wash-out period least 5 day dos .</brief_summary>
	<brief_title>Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion : Clinically stable persistent mild/moderate asthma within 4 week precede screen visit , screen prebronchodilator FEV1 &gt; or=60 % predict , demonstrate presence reversible airway disease , define increase FEV1 &gt; or= 12.0 % max three screen measure absolute change &gt; or= 200 mL within 30 minute follow single 400 mcg salbutamol dose , male female ( non child bear potential meet contraception criterion ) , BMI 1931 kg/m2 , Nonsmoker , refrain use prohibit medication within specify timeframes Exclusion criterion : Pregnant nursing female History life threaten asthma Subjects unable stop take protocol define prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asthmatic Patients</keyword>
</DOC>